Exposure to smoke from high- but not low-nicotine cigarettes leads to signs of dependence in male rats and potentiates the effects of nicotine in female rats

Chellian, Ranjithkumar; Behnood‐Rod, Azin; Wilson, Ryann; Wilks, Isaac; Knight, Parker; Febo, Marcelo; Bruijnzeel, Adrie W.

doi:10.1016/j.pbb.2020.172998

Cited by 17 publications

(20 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On a similar note, chronic exposure to nicotine and tobacco smoke causes reduced body weight gain in rodents. During nicotine withdrawal, body weight returns to baseline levels (Biala and Weglinska, 2005; Chellian et al, 2018, 2020; Grabus et al, 2005; Ponzoni et al, 2015; Small et al, 2010). This pattern of results suggests that exposure to nicotine or smoke and withdrawal has a similar effect on body weights in rodents and human tobacco users.…”

Section: Discussionmentioning

confidence: 98%

“…Learning and memory deficits, anxiety- and depressive-like behaviors last from day 1 to 90 days after cessation of smoke or e-cig aerosol exposure in mice (Ponzoni et al, 2015, 2020) (Figure 4). In a recent study by our group, mecamylamine-precipitated somatic withdrawal signs were observed in male but not in female rats that had been exposed to tobacco smoke for 35 days (Chellian et al, 2020). Additional studies are needed to study the withdrawal symptoms associated with the cessation of tobacco smoke and e-cig aerosol exposure in rats.…”

Section: Animal Models Of Nicotine Withdrawal Symptomsmentioning

confidence: 99%

“…The mecamylamine-precipitated withdrawal symptoms are more severe in mice exposed to tobacco smoke than in mice exposed to e-cig aerosol (Ponzoni et al, 2015). Also, tobacco smoke, nicotine vapor, or e-cig aerosol exposed rats that were treated with mecamylamine showed precipitated nicotine withdrawal symptoms, including somatic withdrawal signs and depressive-like behavior (anhedonia) (Chellian et al, 2020; Gilpin et al, 2014; Montanari et al, 2020; Small et al, 2010). Cessation of tobacco smoke and e-cig aerosol after seven weeks of exposure in mice leads to somatic withdrawal signs, learning and memory deficits, and anxiety- and depressive-like behavior (Ponzoni et al, 2015, 2020).…”

Section: Animal Models Of Nicotine Withdrawal Symptomsmentioning

confidence: 99%

“…In rats, cessation of a brief period of nicotine vapor exposure (one and 10 days) produces somatic withdrawal signs (Montanari et al, 2020). However, cessation of 2–5 weeks of cigarette smoke exposure did not lead to anxiety- and depressive-like behaviors or cognitive deficits in rats (Chellian et al, 2020; de la Peña et al, 2016). These results suggest that a prolonged period of tobacco smoke, nicotine vapor, or e-cig aerosol exposure is necessary to induce spontaneous affective nicotine withdrawal symptoms in rodents.…”

Section: Animal Models Of Nicotine Withdrawal Symptomsmentioning

confidence: 99%

See 3 more Smart Citations

Rodent models for nicotine withdrawal

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Animal models are critical to improve our understanding of the neuronal mechanisms underlying nicotine withdrawal. Nicotine dependence in rodents can be established by repeated nicotine injections, chronic nicotine infusion via osmotic minipumps, oral nicotine intake, tobacco smoke exposure, nicotine vapor exposure, and e-cigarette aerosol exposure. The time course of nicotine withdrawal symptoms associated with these methods has not been reviewed in the literature. Aim: The goal of this review is to discuss nicotine withdrawal symptoms associated with the cessation of nicotine, tobacco smoke, nicotine vapor, and e-cigarette aerosol exposure in rats and mice. Furthermore, age and sex differences in nicotine withdrawal symptoms are reviewed. Results: Cessation of nicotine, tobacco smoke, nicotine vapor, and e-cigarette aerosol exposure leads to nicotine withdrawal symptoms such as somatic withdrawal signs, changes in locomotor activity, anxiety- and depressive-like behavior, learning and memory deficits, attention deficits, hyperalgesia, and dysphoria. These withdrawal symptoms are most pronounced within the first week after cessation of nicotine exposure. Anxiety- and depressive-like behavior, and deficits in learning and memory may persist for several months. Adolescent (4–6 weeks old) rats and mice display fewer nicotine withdrawal symptoms than adults (>8 weeks old). In adult rats and mice, females show fewer nicotine withdrawal symptoms than males. The smoking cessation drugs bupropion and varenicline reduce nicotine withdrawal symptoms in rodents. Conclusion: The nicotine withdrawal symptoms that are observed in rodents are similar to those observed in humans. Tobacco smoke and e-cigarette aerosol contain chemicals and added flavors that enhance the reinforcing properties of nicotine. Therefore, more valid animal models of tobacco and e-cigarette use need to be developed by using tobacco smoke and e-cigarette aerosol exposure methods to induce dependence.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Animal Models Of Nicotine Withdrawal Symptomsmentioning

confidence: 99%

Section: Animal Models Of Nicotine Withdrawal Symptomsmentioning

confidence: 99%

Section: Animal Models Of Nicotine Withdrawal Symptomsmentioning

confidence: 99%

See 2 more Smart Citations

Rodent models for nicotine withdrawal

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The elevated plus-maze test is used to measure anxiety-like behavior in rodents (Walf and Frye, 2007) and was performed as described in our previous work (Chellian et al, 2020;Qi et al, 2016;Tan et al, 2019).…”

Section: Elevated Plus Maze Testmentioning

confidence: 99%

Oxycodone decreases anxiety-like behavior in the elevated plus-maze test in male and female rats

Bruijnzeel

Behnood‐Rod

Malphurs

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

The prescription opioid oxycodone is widely used for the treatment of pain in humans. Oxycodone misuse is more common among people with an anxiety disorder than those without one. Therefore, oxycodone might be misused for its anxiolytic properties. We investigated if oxycodone affects anxiety-like behavior in adult male and female rats. The rats were treated with oxycodone (0.178, 0.32, 0.56, or 1 mg/kg), and anxiety-like behavior was investigated in the elevated plus-maze test. Immediately after the elevated plus-maze test, a small open field test was conducted to determine the effects of oxycodone on locomotor activity. In the elevated plus-maze test, oxycodone increased the percentage of time spent on the open arms, the percentage of open arm entries, time on the open arms, open arm entries, and the distance traveled. The males treated with vehicle had a lower percentage of open arm entries than the females treated with vehicle, and oxycodone treatment led to a greater increase in the percentage of open arm entries in the males than females. Furthermore, the females spent more time on the open arms, made more open arm entries, spent less time in the closed arms, and traveled a greater distance than the males. In the small open field test, treatment with oxycodone did not affect locomotor activity or rearing. Sex differences were observed; the females traveled a greater distance and displayed more rearing than the males. In conclusion, oxycodone decreases anxiety-like behavior in rats, and oxycodone has a greater anxiolytic-like effect in males than females.

show abstract